Replidyne has cut about a third of its workforce and dumped one of its development programs in a restructuring. The company announced that most of the cuts were in administration, clinical, regulatory, and commercial operations while it was suspending work on a topical antibiotic, REP8839. A late-stage trial for faropenem in acute exacerbation of chronic bronchitis is continuing. Replidyne was a 2006 Fierce 15 [1] company.
- check out this release [2]
- here's the AFX report [3] on the restructuring
Related Articles:
FDA rejects Replidyne's antibiotic. Report [4]
Replidyne files for $100M IPO. Report [5]
Links:
[1] http://www.fiercebiotech.com/Fierce15/2006/replidyne.asp
[2] http://www.fiercebiotech.com/press-releases/press-release-replidyne-provides-strategic-update
[3] http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-21569501.htm
[4] http://www.fiercebiotech.com/story/fda-rejects-replidyne-s-antibiotic/2006-10-23
[5] http://www.fiercebiotech.com/story/replidyne-files-for-100m-ipo/2006-04-06